Showing results (111-120 of 126) with videos related to
Sort By:
Pageof 13
Haematologica|April 2, 2026
Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemiaGuillaume Berton, Jan Philipp Bewersdorf, Julia Gilhodes, et al.Science Translational Medicine|July 12, 2019
A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndromeSabrina Bondu, Anne-Sophie Alary, Carine Lefèvre, et al.Blood|October 24, 2025
Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trialNicolas Boissel, Sylvie Chevret, Françoise Rigal-Huguet, et al.Hemasphere|July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AMLDavid A Sallman, Rami S Komrokji, Amy E Dezern, et al.Bulletin Du Cancer|September 12, 2024
[Nurturing and growing a community of department heads: Act 2 in haematology]Roch Houot, Claire Calmettes, Sophie Park, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic LeukemiaPatrice Chevallier, Thibaut Leguay, Marc Delord, et al.Leukemia|March 6, 2020
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international studyMaximilian Stahl, Rory M Shallis, Wei Wei, et al.Nature Communications|April 8, 2024
Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutationDavid Rombaut, Carine Lefèvre, Tony Rached, et al.Leukemia|May 12, 2026
Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangementBenoit Ducourneau, Arnaud Pages, Stéphanie Struski, et al.Leukemia|November 14, 2022
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILOPierre-Yves Dumas, Emmanuel Raffoux, Emilie Bérard, et al.Pageof 13